Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian E James

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Opinion in Pharmacology|May 22, 2002
Novel bone antiresorptive approachesMichael W Lark, Ian E James
Clinical Pharmacology in Drug Development|July 10, 2019
A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid ReceptorIan E James, Franck Skobieranda, David G Soergel, et al.
Clinical Pharmacology in Drug Development|September 4, 2021
Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy AdultsKimberly A Ramos, Ian E James, Franck Skobieranda, et al.
CNS Drugs|July 18, 2020
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy SubjectsMichael J Fossler, Virginia Schmith, Stephen A Greene, et al.
Arthritis and Rheumatism|May 15, 2003
Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokinesParth Patwari, Michael N Cook, Michael A DiMicco, et al.
Pain|June 24, 2014
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G Soergel, Ruth Ann Subach, Nancy Burnham, et al.
Arthritis and Rheumatism|October 1, 2009
Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilageYihong Sui, Jennifer H Lee, Michael A DiMicco, et al.
Experimental Diabetes Research|July 15, 2011
A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetesMichael S Scully, Tatiana A Ort, Ian E James, et al.
Molecular Pharmaceutics|April 19, 2005
An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkeyRobert W Marquis, Keith W Ward, Theresa Roethke, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2003
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonistsWilliam H Miller, Peter J Manley, Russell D Cousins, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Opinion in Pharmacology|May 22, 2002
Novel bone antiresorptive approachesMichael W Lark, Ian E James
Clinical Pharmacology in Drug Development|July 10, 2019
A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid ReceptorIan E James, Franck Skobieranda, David G Soergel, et al.
Clinical Pharmacology in Drug Development|September 4, 2021
Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy AdultsKimberly A Ramos, Ian E James, Franck Skobieranda, et al.
CNS Drugs|July 18, 2020
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy SubjectsMichael J Fossler, Virginia Schmith, Stephen A Greene, et al.
Arthritis and Rheumatism|May 15, 2003
Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokinesParth Patwari, Michael N Cook, Michael A DiMicco, et al.
Pain|June 24, 2014
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G Soergel, Ruth Ann Subach, Nancy Burnham, et al.
Arthritis and Rheumatism|October 1, 2009
Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilageYihong Sui, Jennifer H Lee, Michael A DiMicco, et al.
Experimental Diabetes Research|July 15, 2011
A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetesMichael S Scully, Tatiana A Ort, Ian E James, et al.
Molecular Pharmaceutics|April 19, 2005
An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkeyRobert W Marquis, Keith W Ward, Theresa Roethke, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2003
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonistsWilliam H Miller, Peter J Manley, Russell D Cousins, et al.
Pageof 2